Clinical Outcomes And Safety Of The Smartsurface Technique In Refractive Surgery: Pilot Free Paper

To evaluate visual outcomes, safety, and patient tolerance of the SmartSurface refractive surgery technique in a pilot cohort.

Single-center pilot study

Patients aged 18 to 40 years undergoing surface ablation with the SmartSurface technique

Study period: January 2025 to December 2025

Ethics approval obtained; informed consent from all participants

Prospective observational study including 40 patients (80 eyes)

Preoperative assessment: uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), refractive error, corneal topography

Postoperative outcomes measured at 1 week, 1 month, and 3 months: UCVA, BCVA, epithelial healing time, patient-reported discomfort, and complications

Data analyzed as mean plus/minus standard deviation for continuous variables and percentages for categorical variables

40 patients (80 eyes), mean age 26 plus/minus 5 years, 55 percent male

Preoperative spherical equivalent: minus 5.8 plus/minus 2.0 diopters

UCVA greater than or equal to 20/25 in 70 of 80 eyes (88 percent) at 1 month

BCVA was maintained or improved in all eyes

Mean epithelial healing time: 4 plus/minus 1.2 days

Patient-reported mild discomfort in 12 eyes (15 percent); no severe pain was reported

No significant intraoperative or postoperative complications observed

The SmartSurface technique for surface ablation refractive surgery demonstrates excellent visual outcomes, rapid epithelial healing, and high patient tolerance. These early results support the safety and effectiveness of the technique and suggest potential advantages in postoperative recovery and patient satisfaction.